Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Schering Partners With Polish Biotech Firm To Provide Recombinant Insulin To China's Exploding Diabetics Population

This article was originally published in The Pink Sheet Daily

Executive Summary

Bayer's antidiabetes drug Glucobay (acarbose), an alpha-glucosidase inhibitor, is already one of the company's strongest products in China.

You may also be interested in...



Primary Care Focus Is Key To Bayer's Leading Position In China

Bayer Schering Pharma didn't become the number one health care company in China simply through the merger of Bayer and compatriot Schering AG in 2006. "The pure act of merging would not have been enough; we would only have been number six" in China, explains Liam Condon, managing Director of Bayer HealthCare China, which reported 2008 sales of over $750 million and over 50 percent growth

Primary Care Focus Is Key To Bayer's Leading Position In China

Bayer Schering Pharma didn't become the number one health care company in China simply through the merger of Bayer and compatriot Schering AG in 2006. "The pure act of merging would not have been enough; we would only have been number six" in China, explains Liam Condon, managing Director of Bayer HealthCare China, which reported 2008 sales of over $750 million and over 50 percent growth

Bayer’s Asia Pacific Regional Head Chris Lee On Bayer’s New Global R&D Center In Beijing And China’s Rising 21st Century Importance: An Interview With PharmAsia News

Bayer Schering Pharma Asia Pacific's Regional Head Chris Lee recently discussed with PharmAsia News' China Bureau Bayer's plans to create a new €100 million research and development center in Beijing and China's strengthening role in the company's 21st century blueprints for expansion. Bayer Schering's first global R&D center in Asia is slated to be operational by 2010, and will be the third in a triumvirate of research outposts that Bayer oversees worldwide (PharmAsia News, Feb. 19, 2009).

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel